October 31, 2016
The Pharmaceuticals and Medical Devices Agency (PMDA) is reviewing the risk of pemphigoid for five DPP-4 inhibitor preparations, including Takeda Pharmaceutical’s Inisync (alogliptin + metformin) - a move that is likely to result in label changes. Four other DPP-4 products...read more